List view / Grid view
29 April 2019 | By European Pharmaceutical Review
In a ruling handed down by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent.
28 March 2019 | By European Pharmaceutical Review
In a ruling handed down on 27 March 2019 by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be rewarded with a patent...
29 October 2018 | By Charles River
Timelines, budgets and regulatory constraints have grown alongside that of the Quality Control (QC) lab’s position in drug development. The main goal of the lab and more widely of the manufacturing industry is to increase safety for the end user and guarantee patients’ health...
2 January 2018 | By Christof Hohne
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
3 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine...
30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma
Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…
23 May 2017 | By Niamh Marriott, Junior Editor
The State Patent Bureau of the Republic of Lithuania (SPB) and Kaunas University of Technology National Innovation and Entrepreneurship Centre (KTU NIEC) has signed the collaboration agreement, which laid foundation for the new Patent Library – PATLIB Centre. This will be the first time, when a PATLIB Centre is established…
11 October 2016 | By Vanessa Rieu and Annsley Merelle Ward
Vanessa Rieu and Annsley Merelle Ward explain how life sciences companies can leverage their knowledge of national patent laws in a post-Brexit Europe...
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The Patent Trial and Appeal Board (PTAB) found that the patent was valid in light of the challenges put forward by the petitioner...
27 September 2016 | By Dominic Adair and Emma Muncey, Bristows
Top litigators Dominic Adair and Emma Muncey review patent court cases to identify the legal steps you should take when marketing a biosimilar...
29 March 2016 | By Victoria White
The US District Court for Southern Florida has upheld Shire's patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis...
17 March 2016 | By Victoria White
Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity...
10 March 2015 | By David Elder (JPAG member and consultant)
The World Health Organisation (WHO) in 2010 described counterfeit medicines as those which are “Deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active…
24 February 2015 | By Kuros
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947...
Follow: